- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02212886
Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 or 40 mg GA Depot in Subjects With RRMS
November 14, 2023 updated by: Mapi Pharma Ltd.
A Prospective 1-year, Open-label, Two Arms, Multicenter, Phase IIa Study to Assess Safety, Tolerability and Efficacy of Once a Month Long-acting Intramuscular Injection of 80 or 40 mg Glatiramer Acetate (GA Depot) in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
- This is a phase IIa study in which GA Depot 80 or 40mg is administered as an IM injection to subjects with RRMS at 4 week intervals for 52 weeks of treatment.
- The purpose of the study is to assess safety, tolerability, and efficacy of a monthly long-acting IM injection of 80 or 40mg GA Depot in subjects with RRMS. The study will include subjects switching from daily or thrice weekly administration of 20 mg or 40mg respectively of glatiramer acetate (GA, i.e., Copaxone®) injection
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
- 25 Subjects with a diagnosis of relapsing remitting multiple sclerosis (RRMS) who are treated with daily or thrice weekly subcutaneous injections of 20 mg or 40 mg respectively of GA (Copaxone®) during the previous 12 months
- Study product is GA long-acting injection (GA Depot) which is a combination of extended-release microspheres for injection and diluent (water for injection) for parenteral use. GA Depot will be administered intramuscularly (IM).
- The study duration for an individual subject in the core study will be 60 weeks, consisting of 4 weeks of screening evaluation (weeks -4 to 0), followed by a 52-week open-label treatment period, and a 4 weeks follow up period: through a total of 17 visits.
- For both arms, subjects who completed 13 injections and who consented (by signing an informed consent) are able to enter the optional 8 years extension period. During the extension period subjects will receive 40 mg of GA Depot IM once every 4 weeks.
- Physical, vital signs and safety assessment - will be performed at each visit during the whole study. Physical examination will be performed quarterly during the extension period.
- MRI at visit 1 (screenings), at week 24, week 52 (end of core study) and every 6 months during the extension period.
- Neurological and safety laboratory tests at screening visit, on visits in weeks 4, 12, 24, 36, 52 (end of core study) and every 6 months during the extension period.
Study Type
Interventional
Enrollment (Actual)
25
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Ashkelon, Israel
- Barzilai Medical Center
-
Haifa, Israel
- Rambam Medical Center
-
Tel Aviv, Israel
- TASMC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 68 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Male or female subjects with a diagnosis of RRMS.
- Diagnosis of multiple sclerosis (MS) consistent with the McDonald Criteria (revisions of 2010).
- Treatment with 20 mg or 40 mg of GA (Copaxone®) during the previous 12 months with ongoing treatment at the Screening Visit.
- Normal renal function.
- Normal liver function.
- Normal hemoglobin concentration.
- Absence of any clinically significant medical, psychiatric or laboratory abnormalities.
- Ability to provide written informed consent.
Exclusion Criteria:
- Any relevant medical, surgical, or psychiatric condition, laboratory value, or concomitant medication which, in the opinion of the investigator, makes the subject unsuitable for study entry or potentially unable to complete all aspects of the study.
- Concomitant Autoimmune disease.
- Severe anemia (hemoglobin < 10 g/dL).
- Abnormal renal function (serum creatinine > 1.5xULN).
- Abnormal liver function (transaminases >2xULN).
- Pregnant or breast-feeding women.
- Women capable of child bearing must have a negative urine pregnancy test at screening visit and use an adequate contraceptive method throughout the study. Women who are surgically sterile (hysterectomy or tubal ligation) or whose last menstruation was 12 months or more prior to the Screening Visit are considered to be of non-child-bearing potential. Acceptable forms of contraception include oral, implanted, or injected contraceptives; intrauterine devices in place for at least 3 months; estrogen patch; and adequate barrier methods in conjunction with spermicide. Abstinence is considered an acceptable contraceptive regimen.
- History of any anaphylactic reaction and/or serious allergic reaction following a vaccination, a proven hypersensitivity to any component of the study drug, e.g. GA, polylactic-co-glycolic acid (PLGA), polyvinyl alcohol (PVA).
- Known or suspected history of drug or alcohol abuse.
- Positive test for HIV, hepatitis, venereal disease research laboratory test (VDRL), or tuberculosis.
- Participation in an investigational drug study within 30 days prior to start of this study.
- Active malignant disease of any kind. However, a patient, who has had a malignant disease in the past, was treated and is currently disease - free for at least 5 years, may be considered to be enrolled in the study. In this case the sponsor medical expert approval is required.
- Treatment with any kind of steroids during the last 30 days.
- Confirmed relapse during the last 30 days.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: GA Depot 80mg
Monthly IM injection
|
Recruitment completed
Other Names:
|
Experimental: GA Depot 40mg
Monthly IM injection
|
Recruitment completed
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety / Adverse events
Time Frame: During the study (1 year treatment)
|
Number of patients experiencing adverse events and assessments of localized skin reactions at injection sites.
|
During the study (1 year treatment)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy/Change in Relapse Rate
Time Frame: During the study (1 year treatment)
|
Relapse rate detected during the study compared to relapse rate observed in the 12 months prior to study start.
|
During the study (1 year treatment)
|
Efficacy/Changes in brain MRI
Time Frame: During the study (1 year treatment)
|
Changes from baseline to end of treatment visit in the number of enhancing lesions and new lesions images of brain MRI
|
During the study (1 year treatment)
|
Efficacy/Changes in EDSS
Time Frame: 1 year
|
Change from baseline to end of treatment visit of Expanded Disability Status Scale (EDSS) score.
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Shlomo Flechter, M.D
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 1, 2014
Primary Completion (Actual)
May 1, 2017
Study Completion (Estimated)
November 1, 2024
Study Registration Dates
First Submitted
August 5, 2014
First Submitted That Met QC Criteria
August 6, 2014
First Posted (Estimated)
August 8, 2014
Study Record Updates
Last Update Posted (Actual)
November 15, 2023
Last Update Submitted That Met QC Criteria
November 14, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MI GA Depot - 001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
-
Brigham and Women's HospitalMassachusetts General HospitalRecruitingMultiple Sclerosis | Relapsing Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
University of MinnesotaMallinckrodtTerminatedPrimary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
Clinical Trials on GA Depot 80 mg
-
Mapi Pharma Ltd.Active, not recruitingPrimary Progressive Multiple SclerosisIsrael, Moldova, Republic of
-
Genencell Co. Ltd.Recruiting
-
RemeGen Co., Ltd.RecruitingPrimary Sjogren's SyndromeChina
-
Allist Pharmaceuticals, Inc.Not yet recruiting
-
Mapi Pharma Ltd.CompletedMultiple Sclerosis, Relapsing-RemittingUnited States, Belarus, Bosnia and Herzegovina, Bulgaria, Estonia, Georgia, Israel, Moldova, Republic of, Russian Federation, Ukraine
-
IpsenRecruitingPrimary Sclerosing CholangitisUnited States, Spain, Germany, Canada, United Kingdom, Italy, Portugal
-
AbbottFraktal.com.pl; Med-net.plCompletedLower Urinary Tract Symptoms | Advanced Prostate CancerPoland, Ukraine
-
AstraZenecaActive, not recruitingStage IB-IIIA Non-small Cell Lung CarcinomaUnited States, Italy, Netherlands, Belgium, Canada, Poland, Romania, Taiwan, Thailand, Vietnam, France, Brazil, Hungary, Japan, Russian Federation, Turkey, China, Korea, Republic of, Germany, Hong Kong, Spain, Australia, Israel, Ukraine, Swed...
-
IpsenRecruitingPrimary Biliary Cholangitis (PBC)United States, Spain, Romania
-
TakedaCompleted